Horizon Pharma plc Launches GoutRevealed.com to Spotlight the Journey and Stories of People Living with Uncontrolled Gout
22. Mai 2018 09:00 ET
|
Horizon Pharma plc
DUBLIN, Ireland, May 22, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP) today marked Gout Awareness Day with the launch of Gout Revealed, which was created to spotlight real-life stories...
Horizon Pharma plc Reports Strong First-Quarter 2018 Orphan and Rheumatology Net Sales Growth; Increases Full-Year 2018 Guidance and Announces New Company Operating Structure to Enhance Focus on Rare Diseases
09. Mai 2018 07:00 ET
|
Horizon Pharma plc
-- First-Quarter 2018 Orphan and Rheumatology Net Sales of $172.2 Million Increased 11 Percent;Represented 77 Percent of Total Company Net Sales -- -- First-Quarter 2018 KRYSTEXXA Net Sales Growth of...
Horizon Pharma Gift Establishes First Clinical Team Endowment at Children’s National Rare Disease Institute
26. Februar 2018 08:00 ET
|
Horizon Pharma plc
WASHINGTON, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Children’s National Health System and Horizon Pharma plc are pleased to announce the creation of the Horizon Pharma Clinical Care Endowment, the first...
Horizon Pharma plc Presents Results from an Open-Label Study on the Use of PROCYSBI® (cysteamine bitartrate) Delayed-Release Capsules in Treatment-Naïve Children Younger than 6 Years of Age
04. November 2017 11:00 ET
|
Horizon Pharma plc
DUBLIN, Ireland, Nov. 04, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...
Horizon Pharma plc Announces Poster Presentation on KRYSTEXXA® (pegloticase injection) at the American Society of Nephrology Kidney Week 2017
03. November 2017 11:00 ET
|
Horizon Pharma plc
DUBLIN, Ireland, Nov. 03, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...
Horizon Pharma plc to Present KRYSTEXXA® (pegloticase injection) Data for the Management of Uncontrolled Gout at the 2017 ACR/ARHP Annual Meeting
23. Oktober 2017 08:00 ET
|
Horizon Pharma plc
-- Initial data from investigator-initiated TRIPLE study to be presented on Nov. 6 -- -- Horizon Pharma plc to host an investor call on Nov. 9 following the ACR/AHRP Annual Meeting -- DUBLIN,...
INVESTOR ALERT: Rosen Law Firm Reminds Horizon Pharma plc Investors of Important May 9 Deadline in Class Action – HZNP
28. April 2016 18:06 ET
|
The Rosen Law Firm PA
NEW YORK, April 28, 2016 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Horizon Pharma plc securities (NASDAQ:HZNP) from March 13, 2014 through...
DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders Of Horizon Pharma plc Of Upcoming Deadline -- HZNP
26. April 2016 15:16 ET
|
Rigrodsky Law, P.A
WILMINGTON, Del., April 26, 2016 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A.: Do you, or did you, own shares of Horizon Pharma plc (NASDAQ:HZNP)?Did you purchase your shares between March 13,...
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Horizon Pharma plc – HZNP
12. April 2016 13:43 ET
|
The Rosen Law Firm PA
NEW YORK, April 12, 2016 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Horizon Pharma plc...
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Horizon Pharma plc
11. März 2016 16:12 ET
|
Rigrodsky Law, P.A
WILMINGTON, Del., March 11, 2016 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A.: Do you, or did you, own shares of Horizon Pharma plc (NASDAQ:HZNP)?Did you purchase your shares between March...